Immunotherapy and targeted drug after chemoradiation for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding two medications—tislelizumab (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted drug that blocks blood supply to tumors)—after standard chemoradiation can help keep limited-stage small cell lung cancer from coming back. It may offer a new option to improve outcomes for patients who have already responded to initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with limited-stage small cell lung cancer (cancer that is only in one lung and nearby lymph nodes).
- You have completed chemoradiation (chemotherapy and radiation) and your cancer has shrunk or stayed the same (not grown).
- You are able to take care of yourself (ECOG performance status 0 or 1).
- You have adequate organ function and a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (tislelizumab and nintedanib) given after initial chemotherapy and radiation to help prevent the cancer from coming back. It is for people with limited-stage small cell lung cancer.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy (and sometimes radiation) for people with small cell lung cancer that has spread to only a few spots in the body. The goal is to see if adding immunotherapy helps control the cancer better than chemotherapy alone.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This trial tests a combination of two drugs — sintilimab (an immunotherapy) and anlotinib (a targeted therapy) — for people with small cell lung cancer that has worsened after previous immunotherapy. The goal is to see if this combination can help control the cancer when standard treatments have stopped working.
This study is testing a new combination treatment for early-stage small-cell lung cancer. It compares giving immunotherapy drugs (PD-1/PD-L1 inhibitors) along with chemotherapy before surgery versus chemotherapy alone, to see if the combination helps shrink tumors more effectively and improves outcomes.
Hear when a new SCLC, Limited Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.